PhD Research Scholar Manipal College of Pharmaceutical Sciences Udupi, Karnataka, India
Introduction: Breast cancer remains a leading cause of mortality, demanding advanced therapeutic approaches to address limitations including low specificity, multidrug resistance, and systemic toxicity of conventional treatments. Everolimus (EVR), an mTOR inhibitor approved for hormone receptor-positive, HER2-negative advanced breast cancer, exhibits potent antitumor activity but suffers from poor aqueous solubility, limited bioavailability, and off-target toxicity to healthy cells. This study aims to develop folic acid-conjugated, polydopamine-coated everolimus-loaded mesoporous silica nanoparticles (FA-PDA-EVR-MSNs) to enhance targeted delivery, and therapeutic performance.
Learning Objectives:
Rationale for developing FA-conjugated, PDA-coated MSNs to improve everolimus delivery in breast cancer therapy
Preparation and evaluation of MSNs, surface modification, and characterization techniques for FA-PDA-EVR-MSNs
Evaluate pH-responsive release and folate targeting in FA-PDA-EVR-MSNs to enhance EVR efficacy
